Ev3 Atherectomy Biz Stabilizing After Sales Force Improvements, Firm Says
This article was originally published in The Gray Sheet
Ev3 believes a sales force restructuring initiated earlier this year is bearing fruit for its struggling atherectomy business
You may also be interested in...
ev3 is expanding its neurovascular division, already the fastest-growing segment of the company, by buying Chestnut Medical Technologies for $75 million up-front and up to $75 million in milestone payments, the companies announced June 2
Endovascular device firm ev3's formerly rocky marriage with FoxHollow is now on steadier ground with a better-than-expected recovery of its atherectomy business in the second quarter
New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.